Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
VRCA
Undervalued
Verrica Pharmaceuticals Inc.
Price$4.18
Model IV$5.34
P/IV0.87
Discount 22%
Return to IV: +27.7%
Market implies -3.6%/yr
vs model +31.2% · below model
VRDN
Deeply overvalued
Viridian Therapeutics, Inc.DE
Price$18.34
Model IV$5.35
P/IV4.01
Premium +243%
Return to IV: -70.8%
Market implies +14.5%/yr
vs model +50.0% · below model
VRTX
Deeply overvalued
VERTEX PHARMACEUTICALS INC / MA
Price$503.25
Model IV$277.42
P/IV1.90
Premium +81%
Return to IV: -44.9%
Market implies +16.1%/yr
vs model +10.7% · above model
VSTM
Deeply overvalued
Verastem, Inc.
Price$8.11
Model IV$2.42
P/IV1.79
Premium +235%
Return to IV: -70.2%
Market implies +17.1%/yr
vs model +50.0% · below model
VTGN
Valuation N/A
Vistagen Therapeutics, Inc.
Price$0.25
Model IV—
P/IV—
Market implies +40.3%/yr
vs model +2.0% · above model
VTRS
Undervalued
Viatris Inc
Price$17.44
Model IV$22.82
P/IV0.71
Discount 24%
Return to IV: +30.8%
Market implies -1.1%/yr
vs model +2.9% · below model
VTVT
Valuation N/A
vTv Therapeutics Inc.
Price$30.08
Model IV—
P/IV—
Limited data — see page
VYNE
Valuation N/A
VYNE Therapeutics Inc.
Price$28.56
Model IV—
P/IV—
Market implies +139.7%/yr
vs model +2.0% · above model
WHWK
Valuation N/A
Whitehawk Therapeutics, Inc.
Price$3.47
Model IV—
P/IV—
Market implies +63.3%/yr
WVE
Valuation N/A
Wave Life Sciences Ltd.
Price$3.47
Model IV—
P/IV—
Market implies +84.7%/yr
vs model +2.0% · above model
XBIO
Fairly valued
Xenetic Biosciences, Inc.
Price$2.12
Model IV$1.88
P/IV1.34
Premium +13%
Return to IV: -11.6%
Market implies +0.3%/yr
vs model +26.5% · below model
XBIT
Valuation N/A
XBiotech Inc.
Price$2.20
Model IV—
P/IV—
Market implies +31.1%/yr
vs model +15.0% · above model
XCUR
Valuation N/A
EXICURE, INC.
Price$1.00
Model IV—
P/IV—
Market implies +25.2%/yr
vs model +15.0% · above model
XENE
Valuation N/A
Xenon Pharmaceuticals Inc.
Price$36.16
Model IV—
P/IV—
Market implies +101.1%/yr
vs model +2.0% · above model
XERS
Deeply undervalued
Xeris Biopharma Holdings, Inc.
Price$10.19
Model IV$17.20
P/IV0.36
Discount 41%
Return to IV: +68.8%
Market implies -10.8%/yr
vs model +50.0% · below model
XLO
Fairly valued
Xilio Therapeutics, Inc.
Price$9.01
Model IV$8.45
P/IV1.00
Premium +7%
Return to IV: -6.2%
Market implies -7.2%/yr
vs model +15.0% · below model
XNCR
Valuation N/A
Xencor Inc
Price$24.50
Model IV—
P/IV—
Market implies +47.1%/yr
XOMA
Valuation N/A
XOMA Royalty Corp
Price$40.17
Model IV—
P/IV—
Market implies +69.6%/yr
vs model +2.0% · above model
XOMAO
Valuation N/A
XOMAO
Price$25.00
Model IV—
P/IV—
Limited data — see page
XOMAP
Valuation N/A
XOMAP
Price$24.98
Model IV—
P/IV—
Limited data — see page
XRTX
Valuation N/A
XORTX Therapeutics Inc.
Price$1.85
Model IV—
P/IV—
Limited data — see page
XTLB
Valuation N/A
XTL BIOPHARMACEUTICALS LTD
Price$1.99
Model IV—
P/IV—
Market implies +141.2%/yr
vs model +15.0% · above model
ZBIO
Valuation N/A
Zenas BioPharma, Inc.
Price$26.24
Model IV—
P/IV—
Market implies +88.9%/yr
vs model +2.0% · above model
ZLAB
Valuation N/A
Zai Lab Ltd
Price$24.81
Model IV—
P/IV—
Market implies +37.7%/yr
vs model +33.5% · above model
ZNTL
Valuation N/A
Zentalis Pharmaceuticals, Inc.
Price$2.51
Model IV—
P/IV—
Market implies +9.1%/yr
ZTS
Deeply undervalued
Zoetis Inc.
Price$73.08
Model IV$125.29
P/IV0.57
Discount 42%
Return to IV: +71.4%
Market implies -0.1%/yr
vs model +8.5% · below model
ZVRA
Fairly valued
ZEVRA THERAPEUTICS, INC.
Price$11.00
Model IV$12.28
P/IV0.94
Discount 10%
Return to IV: +11.6%
Market implies -6.5%/yr
vs model +38.8% · below model
ZYBT
Deeply overvalued
Zhengye Biotechnology Holding Ltd
Price$1.15
Model IV$0.39
P/IV2.18
Premium +195%
Return to IV: -66.1%
Market implies +19.5%/yr
vs model +10.0% · above model
ZYME
Deeply overvalued
Zymeworks Inc.
Price$25.26
Model IV$6.47
P/IV4.25
Premium +290%
Return to IV: -74.4%
Market implies +16.8%/yr
vs model +41.2% · below model